Facility will be the first fill-finish site for Lonza.
To build on existing parenteral drug product development and testing capabilities, Lonza Pharma & Biotech has agreed to purchase a fill-finish facility in Stein, Switzerland from Novartis. With the addition of this site to its network, Lonza will be able to offer end-to-end services for clinical supply and commercial launch of parenteral drug products.
The financial terms of the deal were not disclosed, but it is expected to be finalized within a few months. Lonza will continue to produce products for Novartis, as well as take on contract manufacturing projects for other customers. The facility, which currently serves as the Novartis Center of Excellence for sterile clinical (phases I to III) drug product manufacturing, is designed for multi-product production.
